
QUANTiSCOPE automates the extraction of quantitative phenotypic data from microscopic images to speed decision-making in drug discovery. The company uses AI and deep learning—branded as the PhenotypIQ® digital twin platform—to analyze fluorescent and brightfield images and produce plug-and-play dashboards and QC metrics for biologic, chemical, and genetic therapy workflows. Its platform is positioned as a B2B SaaS solution for researchers, biotechs, and bio-manufacturing teams and integrates with high-content imaging pipelines and laboratory workflows. QUANTiSCOPE emphasizes applications such as nanoparticle vaccine and gene therapy quality control and aims to reduce resource use and improve safety in development pipelines.

QUANTiSCOPE automates the extraction of quantitative phenotypic data from microscopic images to speed decision-making in drug discovery. The company uses AI and deep learning—branded as the PhenotypIQ® digital twin platform—to analyze fluorescent and brightfield images and produce plug-and-play dashboards and QC metrics for biologic, chemical, and genetic therapy workflows. Its platform is positioned as a B2B SaaS solution for researchers, biotechs, and bio-manufacturing teams and integrates with high-content imaging pipelines and laboratory workflows. QUANTiSCOPE emphasizes applications such as nanoparticle vaccine and gene therapy quality control and aims to reduce resource use and improve safety in development pipelines.
Product: AI-driven image analysis platform (PhenotypIQ) for quantitative phenotypic data from microscopic images
Customers: Researchers, biotechs, and bio-manufacturing teams (B2B SaaS)
Founded: 2022
Headquarters: Salt Lake City, Utah, United States
Funding: Grant round with First Flight Venture Center
Automating image-based phenotypic quantification to improve throughput and decision-making in drug discovery and bio-manufacturing quality control.
2022
Biotechnology
5000 USD
“First Flight Venture Center (lead for grant round)”